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Abstract 
Patient motion can cause misalignment of the tumour and toxicities to the healthy lung tissue 
during lung stereotactic body radiation therapy (SBRT). Any deviations from the reference setup 
can miss the target and have acute toxic effects on the patient with consequences onto its quality 
of life and survival outcomes. Correction for motion, either immediately prior to treatment or 
intra-treatment, can be realized with image-guided radiation therapy (IGRT) and motion 
management devices. The use of these techniques has demonstrated the feasibility of integrating 
complex technology with clinical linear accelerator to provide a higher standard of care for the 
patients and increase their quality of life. 
 
1. Introduction 
Lung Stereotactic Body Radiation Therapy (SBRT), or stereotactic ablative body radiotherapy 
(SABR), is a radiation therapy technique that delivers large ablative doses to the tumour with 
fewer fractions than conventional radiation therapy. The high biological dose delivered to 
patients requires a high conformal dose distribution around the tumour with minimal exposure of 
surrounding healthy tissues. However, lung tumours are subjected to motion, which complicates 
the provision of high accuracy targeting during treatment delivery. Failure to adequately account 
for uncertainties due to motion can cause geographic miss and inaccurate dose coverage, such as 
underdosing the target and/or overdosing surrounding organs-at-risk (OAR) [1-4]. For these 
reasons, it is a desideratum of modern radiotherapy to manage tumour motion, trajectory 
irregularities, deformation and patient repositioning during lung radiation therapy. 
 
Image-guided radiation therapy (IGRT) is the image-based guidance of radiotherapy delivery 
and a sub-set of the motion management strategies clinically implemented to help mitigate 
motion-related errors [5]. The scope of this chapter is narrowly defined to IGRT and motion 
management during SBRT delivery of photon beam therapy. The novelty of Magnetic 
Resonance Imaging (MRI) combined with linear accelerators is detailed in another chapter [6] 
and will not be extensively mentioned here. We presuppose that a patient scan has been acquired 
(e.g. 4D-CT, MRI), and a treatment plan appropriate to the delivery method has been developed. 
This chapter is then organised into IGRT and motion management technologies that are used in 
room but prior to the treatment delivery (section II) and those that are used during the treatment 
(section III). 
 
2. In room pre-treatment IGRT and motion management 
Pre-treatment IGRT and motion management techniques available either commercially or in the 
research phase are summarised below in Fig. 1. Each of these devices are compartmentalised into 
four domains; kV imaging, MV imaging, optical imaging and treatment couch. 
2.1. KV imaging 
2.1.1. Conventional kV-imagers and 3D-CBCT 
Fluoroscopic imaging devices are offered as standard components for nearly all linear 
accelerators (linacs). Most C-arm shaped linacs are made available with retractable kilovoltage 
(kV) source and a detector panel that provide a radiographic image of the patient’s anatomy with 
submillimetre resolution enabling highly accurate positioning relative to a reference setup. The 
visibility of internal anatomy using kilovoltage x-rays is largely imposed by the Compton cross 
sections of the targeted tissue in the patient. For that reason, bone and metal (implanted fiducials) 
are high contrast due to their high attenuation coefficient and can be used as landmarks for 
patient’s positioning, as opposed to soft tissue that have a low visibility contrast. 
 
Another system, the Vero system (Brainlab AG, Feldkirchen, Germany) uses gimballed X-ray 
sources and imager. The Cyberknife system (Accuray Inc. Sunnyvale, USA) and the ExacTrac 
X-ray system (ExacTrac optical-tracking system, Brainlab, Heimstetten, Germany) are both 
systems that entail the use of mounted X-ray imagers and in-floor built detectors. 
 
For rotating X-ray gantry, the 2D images can be reconstructed in three dimensions (cone-beam-
computed-tomography, 3D-CBCT). Compared with kV planar images, CBCT provides offers a 
more complete assessment of patient deformation, rotation, tumour to OAR distances [7,8] and 
more importantly, a higher contrast visibility of soft tissue. AAPM Task-group 179 recommends 
quality assurance and iso-calibration tests monthly, to ensure that geometric and image quality 
remain within tolerance, and daily, for safety (collision check) and laser/image/treatment 
isocentre coincidence [9]. 3D-CBCT entails the use of fluoroscopic images and gantry rotation to 
calculate a three dimensional image showing the patient’s internal anatomy prior to each fraction 
and allows visualisation of a range of geometric deviations such as motion-related uncertainties 
[10]. The main drawback of 3D-CBCT for lung imaging is that the projections from breathing 
phases are averaged to reconstruct a single 3D scan. Average projection yields blurred regions of 
interest or multiple diaphragm artefacts [11], potentially providing misinformation regarding 
actual tumour amplitude and its relative position to the OAR during breathing [12]. These 
artefacts complicate the task of the clinician to assess the degree of internal motion, deformation 
and the repositioning of the patient according to the reference set up 
 
2.1.2. 4D-CBCT 
4D-CBCT is the reconstruction of time-resolved 2D projections in phase or amplitude bins. 
Online 4D-CBCT has the advantage over 3D-CBCT of providing daily motion information such 
as visualising lesions that are near the ribs or diaphragm that might be inside 3D-CBCT blur and 
identifying baseline shift [13]. Compared with 3D-CBCT, the 4D-CBCT supplementary 
information on the trajectory-of-the-day keeps the margins around the target small [14] and 
reduces inter-observer variability for patient positioning [15]. 4D-CBCT was first developed and 
implemented on a linac by Tagushi et al. [16] and Sonke et al. [17]. Elekta released the first 
commercially available 4D-CBCT followed by Varian with the Truebeam 2.0. 
 
The image quality of 4D-CBCT is dependent on the binning strategies and the type of CBCT 
reconstruction algorithm. Binning strategies are grouped either by phase or by displacement. 
Phase binning divides the breathing cycle into discrete phases relative to an arbitrary origin (i.e. 
end of exhalation), while displacement uses the magnitude of displacement to discretise the 
breathing signal. Phase binning was shown to be more clinically relevant, with a more accurate 
and clearer representation of small moving structures but the method is weakened in the presence 
of baseline shift [18]. On the other hand, displacement binning has the advantage to be less 
sensitive to variation in breathing patterns during the acquisition but the quality of reconstruction 
is influenced by interbin image quality variation and large projection angular gaps [18]. The 
reconstruction of CBCT is also heavily dependent on the reconstruction algorithm clinically in 
use. The current clinical reconstruction algorithm is the Feldkamp-Davis-Kress (FKD) algorithm 
or the McKinnon-Bates (MKB) algorithm, the latter mostly used for fast reconstruction. Both 
algorithms suffer from streak artefacts and a considerable amount of noise [18] 
 
There is active research towards an enhanced version of 4D-CBCT to decrease the imaging dose 
per acquisition and reduce the streak artefacts. Dose reductions are obtained with hardware 
enhancement by varying the gantry speed [19,20], acquisition and imaging frequency [21] on a 
patient-specific basis in response to the patient’s respiratory signal, with reported ∼50% 
reduction of image dose. Streak artefacts can be reduced by implementing an iterative 
reconstruction algorithm [22]. Iterative algorithms are limited clinically by their requirements for 
long and intensive computation. However, they provide a higher image quality when constraints 
are applied to the similarity between the image to be reconstructed and higher quality prior 
image. 
 
2.2. MV imaging 
2.2.1. Electronic Portal imaging device (EPID) 
The EPID was developed to provide a fast and accessible tool to replace film dosimetry. For 
most C-shaped linear accelerators, the EPID is a retractable panel that can be deployed at 
different distances and is typically used as a quality assurance tool on modern linacs for 
verification of modulated deliveries. For older linacs without on-board imagers, the EPID 
remains the go-to tool for pre-treatment patient setup. Its use in the beam-eye-view is particularly 
well appreciated by clinicians since both the image and the therapeutic MV beam share the same 
isocentre with projection having less distortion from metal artefacts compared with kV imaging. 
The inconvenience of MV X-ray imaging is that high energy photons have low tissue-density 
differentiation, resulting in 2D images with lower contrast-to-noise ratio than kV images. 
Average dose per image is as high as 3–7 cGy, compared with the kV system of 0.1–0.3 cGy per 
images. Better image quality will improve the potential for patient positioning prior to treatment 
using the MV frames. For that reason, efforts have been made to investigate the detectors’ 
response using high efficiency materials [23-26] and enhancing reconstruction algorithms with 
MV-CT and MV-CBCT [27-29]. 
 
2.2.2. Fan beam MV-CT with tomotherapy 
As part of the IGRT techniques utilised before treatment, fan beam MV-CT is available in the 
helical Tomotherapy Hi-ART system (Madison, Wisconsin, USA, HI-ART II). The MV beam 
rotates around the patient in a fast and helical manner, much like a third-generation helical CT 
would (i.e. both X-ray tube and detector rotate). Tomotherapy is the only commercial product 
that currently utilises the MV imaging device in the narrow beam geometry as a computed 
tomographic device. Length in the cranio-caudal (CC) direction is user dependent but the field-
of-view in the other directions is restricted to ∼40 cm. The fan-beam MVCT imaging dose is 
typically in the range of 1–3 cGy per scan [30] depending on the length of the patient to be 
imaged. We like to utilise. 
 
2.2.3. MV-CBCT 
MV-CBCT utilises the EPID to provide reconstructed 3D images prior to treatment. Lower 
energy settings than treatment MV is commonly used, 2.5 MV on the Varian Truebeam linac and 
1 MV for the Siemens linear accelerators. Acquisition and reconstruction are performed in less 
than 2 min with a typical dose between 2 and 9 cGy but motion blur and low density 
differentiation can reduce the image quality. Studies aiming to enhance the image quality utilised 
the MV-CBCT on thoracic scan in a gated rotation acquisition method, where the gantry 
rotations are stopped and started when the tumour reaches the gating threshold [31], or fast 
acquisition, by combining kV and MV projections during approximately 15 s breath-holds [32]. 
For the latter, the gantry needs to rotate only 90 degrees and reduces the acquisition time to ∼15 
s, achievable throughout one breath-hold. This has been automated to be performed clinically 
[33], with patient positioning set up shown to be equivalent to conventional IGRT techniques 
[34]. Additionally, MV-CBCT was shown to be feasible for rapid dose planning in urgent 
palliative situations [35]. 
 
2.3. Optical verification 
Optical IGRT systems dedicated to guidance of patient setup have also been developed, such as 
AlignRT (Vision RT, London, United Kingdom), Catalyst (C-Rad AB, Uppsala, Sweden) and 
ExacTrac optical-tracking system (BrainLab AG, Munich, Germany). These devices rely on 
room-mounted optical cameras that verify the patient position and detect gross alignment errors. 
AlignRT and Catalyst use an infra-red camera that maps the patient surface contours in 6 degrees 
of freedom without the need of markers while the ExacTrac relies on external markers placed on 
the patient’s chest. The ExacTrac also offers the advantage of integration with a kV radiographic 
imaging system to verify the internal markers’ position prior to treatment for building a 
correlation model between external and internal markers. 
 
2.4. Robotic couch 
Treatment couch re-positioning is an important intervention made prior to treatment and is 
closely intertwined with the use of image guidance. The patient is positioned on the couch and 
aligned manually according to landmarks, tattoo or indexed to immobilisation devices. 
Following imaging, the couch can be re-aligned in 3 translations and a couch rotation about the 
anterior-posterior axis (yaw) to match current patient positioning with reference set up. Optimal 
alignment requires 6D correction including the roll and pitch to account for patient internal 
movement and rotation [29,30] to facilitate isocentre shifts. Commercially available 6 degrees of 
freedom couches include the Brainlab’s Robotics 6D couch HexaPOD evo RT (integrated with 
Exactrac X-ray 6D system), Protura Robotic Patient Positioning System (via Civco Medical 
Solution, Kalona, USA), and the PerfectPitch couch system (Varian, Palo Alto, USA). 
 
3. Intra-treatment IGRT and motion management 
During treatment, a range of devices are available for correction of errors related to motion. 
Motion compensation intra-treatment is paramount either by tracking the tumour or monitoring 
and adapting to its position. Fig. 2 summarises the commercial and research applications of the 
IGRT and non-IGRT motion management techniques available during treatment, from beam-on 
until end of treatment. In this section, we restrict the analysis to during treatment as offline 
review can also be processed as an a posteriori treatment quality assurance. 
3.1. Dedicated devices for motion management 
Several motion management devices have been clinically implemented as therapeutic tools to 
ensure a safer and more accurate radiation therapy treatment. These devices rely on motion 
correction in real-time either by adapting the position of the beam, its shape, or the patient couch 
position. The motion input may vary depending on the specific machine, using kV (with or 
without radio-opaque markers), electromagnetic transponders or surface markers for the motion 
of the thorax. 
 
The most prevalent device for motion management with lung tumour tracking is the Cyberknife 
system commercialised and clinically implemented since 2006 [36]. The Cyberknife is 
comprised of a six degree-of-freedom robotic arm capable of compensating for the thoracic 
motion and internal anatomy movement in real-time [37]. Two orthogonal fluoroscopic systems 
are mounted onto the ceiling with the flat panel in-built into the floor around the treatment 
couch. The other commercialised device specifically designed for real-time adaptation is the 
gimballed linac Vero. The Vero linear accelerator is mounted on a ring gantry that rotates both 
around the patient and on its vertical axis (±60 degrees) with two gimbals that enable the 
treatment beam to pan and tilt, a feature particularly useful for tumour tracking [38,39]. For the 
Vero, two kV sources and the flat panel imagers are directly located on the rotating gantry. Both 
the Cyberknife and the Vero tracking system are supplied with a correlation model, initially built 
before treatment, based on the detection motion system of an internal (measured using kV 
imaging) and external (measured using optical imaging) surrogate motion of the chest wall. The 
measured external chest motion combined with the correlation model predicts the tumour 
position, allowing the treatment beam to be shifted accordingly in real-time. For the Cyberknife, 
the correlation model is frequently verified (typically 30–60 s) and updated using marker 
segmentation on a single kV image. For the Vero system, the correlation model is verified more 
frequently than the Cyberknife (1 Hz) but requires treatment interruption to be updated [40]. 
Studies show that patient survival of the Cyberknife and the Vero are equivalent to standard 
SABR [41-45]. These studies also confirm that tumour tracking result in lower toxicity issues 
when compared with standard SABR, with significant increase in dose conformity. 
 
A third technique is dynamic Multi-Leaf Collimator (MLC) tracking for standard linear 
accelerators. MLC tracking takes a tumour position signal and integrates it with the MLC to 
reconfigure the aperture in real-time in response to detected motion. MLC tracking is not 
available commercially but has been demonstrated on Varian [46,47], Elekta [48,49] and 
Siemens [50,51] linear accelerators. One unique possibility presented by MLC tracking is the 
ability to adapt to deformation of a target, which might be best utilised within the MR-linac 
framework. 
 
Couch tracking is another real-time adaptation modality available for the standard linear 
accelerator where a tumour localisation signal is fed back to re-align the treatment couch [52]. 
Couch tracking has not been clinically implemented but has been demonstrated as a proof of 
concept with electromagnetic beacons [53], a topometrical device (Topos, Cyber Technologies, 
Germany), the respiratory gating system RPM (Varian) and a laser triangulation system (Micro 
Epsilon, Ortenburg, Germany) [54]. Couch tracking requires a high-precision couch motion 
system and was shown to be feasibly implemented on most linear accelerators. MLC tracking 
and couch tracking stand as potentially highly accessible modalities to enable increased 
utilisation of real-time adaptive radiotherapy [55]. 
 
3.2. Tracking or monitoring the tumour motion 
kV imagers are an emerging tool for motion management to offer image guidance solutions 
during treatment. Gating or triggered imaging are available on certain linear accelerators (e.g. 
Varian Truebeam) with the capacity to monitor the tumour position, either to deliver the 
therapeutic beam at a specific phage during the patient’s respiratory cycle or for real-time quality 
assurance and treatment accuracy. 
 
The Cyberknife and the Vero systems take advantage of the set of orthogonal kV-imagers and 
optical tracking of external markers. The Cyberknife system includes the Synchrony Respiration 
Tracking System [56,57], a tracking system that reads the Light-Emitting Diodes (LED) chest 
motion input, correlates it with internal motion, and synchronises the beam accordingly with a 
latency of approximately 115 ms [58]. For the Vero, the correlation model is similarly built with 
a system latency for the infra-red markers of approximately 50 ms [39]. This is a much faster 
response time than any other devices because the beam is mounted on gimbals that provide a fast 
mechanical response of the therapeutic beam to be re-oriented. Both the Cyberknife and Vero 
rely on the high contrast of implanted gold markers, like the coiled gold Visicoils (IBA, 
Louvain-la-neuve, Belgium) to guide adaptation. 
 
The Brainlab Exactrac Adaptive Gating system is a device used for patient positioning and intra-
treatment tumour motion monitoring. Its principle is similar to the Cyberknife and Vero as it 
takes advantage of a kV imaging system and chest motion to build a correlation model. Instead 
of tracking the tumour, it monitors the tumour position and irradiates at a selected cycle of 
respiration, during free breathing or deep inhale breath hold (DIBH) [59,60]. Compared with 
continuous tumour tracking, the Exactrac gating system has the disadvantage of increased 
treatment duty cycle, treatment time and imaging. The kV-imagers are mounted on the ceiling 
and floor and work independently from the on-board imaging device of the linear accelerators. 
The system is compatible with Vero and most Varian linear accelerators as an integrated 
platform. 
 
kV-based tracking generally relies on in vivo implanted markers as a surrogate to track tumours 
within kV images acquired during treatment. There are several challenges limiting the utilisation 
of kV marker based tracking for lung SABR including the potential of marker-induced toxicity 
[61-63], marker migration [64] and surrogacy errors between tumour and markers (external or 
internal markers) [65]. Markerless tumour tracking, where automated soft tissue matching is 
performed without implanted markers, has the potential to negate these issues. It must operate 
under the conditions of adequate internal landmark visualisation and surrogacy by the kV-
imaging system or a correlation model coupled with a robust prediction algorithm. For patient 
not amenable for fiducial placement, Cyberknife proposes alternative registration landmarks 
such as spine tracking [66], carina [67,68] or direct tumour tracking [69] with the Xsight lung 
tracking system. Soft-tissue matching using MLC tracking has been tested in a feasibility study 
using offline kilovoltage projections based on a Bayesian approach [70]. Quality assurance for 
markerless tumour tracking may also pose some challenges and require specialist and possibly 
patient specific motion phantoms. 
 
3.3. MV imaging 
3.3.1. MV tumour tracking 
Lung megavoltage tumour tracking is predominantly a type of markerless tracking, based on the 
tumour or surrogate landmarks featured onto the EPID. To our knowledge, MV tracking has 
never been clinically implemented on linear accelerators. It was tested as a proof-of-concept 
using the “STiL” algorithm combined with MLC tracking to visualise and adapt the conformal 
MLC that is shaped according to a 3D printed tumour inside a deformable thoracic phantom [71]. 
With SBRT and modulated plans, one problem is that the tumour is not continuously visible on 
the images and its visibility can be obstructed by the diaphragm, ribs or heart. Also, the use of 
modulated fields complicates the tasks where the lesions are often obscured by the MLC. 
 
3.3.2. EPID-based Intra-treatment dose verification 
EPID-based in vivo dosimetry is the verification of the cumulative dose by comparison with the 
reference planned dose. EPID-based in vivo dosimetry is a system that flags major errors 
resulting from large clinical deviations such as machine fault, human error or large and 
unnoticed patient movement during treatment. A recent study from the Netherlands showed the 
effectiveness of this system [72] claiming that 1 in 300 plans required the inspection of a medical 
physicist to address clinical relevant deviations. Several countries have now integrated EPID-
based in vivo dosimetry as part of their compulsory protocols. Commercial products currently 
available are the EPIDose (Sun Nuclear Corporation, Melbourne, FL), Portal Dosimetry system 
(Varian Medical Systems, Palo Alto, CA), EPIgray (DOSIsoft, Cachan, France), and Dosimetry 
Check (Math Resolutions LLC, USA). However, with the current increase in biological dose 
used for SBRT fractionation, post-delivery analysis is not suitable for avoiding radiation-induced 
toxicities. Real-time EPID-based dose verification can mitigate these issues. Although never 
implemented for the lung, the use of the EPID for real-time dose verification (“WatchDog”) has 
been clinically tested on a cohort of 28 patients with head-and-neck and prostate cancer [73] 
allowing for both real-time dosimetric and geometric quality control. 
 
3.4. Electromagnetic transponders 
As a non-imaging based motion management technique, the use of electromagnetic transponders 
for lung tumour tracking is potentially the most advanced. This system uses non-ionising 
alternating current electromagnetic radiation to locate and continuously track small devices. It 
relies on a set of electromagnetic transponders (bronchoscopically or percutaneously) inserted in 
the vicinity of the lung tumour to be wirelessly detected by a detector placed above the patient 
chest during treatment (Fig. 3). Electromagnetic beacons for real-time tumour tracking in 
radiation therapy are commercialised by RayPilot (Micropos Medical AB, Gothenburg, Sweden) 
and the Calypso Anchored Beacons System (Calypso, Varian Medical system). Both products 
are suited for use on conventional linac. Micropos rely on wired beacons that are intended to be 
retracted after treatment. Although this technique has demonstrated its feasibility for prostate, the 
use of Micropos for lung has never been tested. The Calypso beacons are permanently implanted 
near the tumour. For lung insertion, Varian provides an improved version of regular prostate 
beacons with a five legged nitinol stability feature to facilitate anchoring within small airways 
[74]. The Calypso beacons for lung are approved for gated lung SABR and motion monitoring 
for data acquisition and analysis by numerous Government Regulatory bodies, such as the TGA 
in Australia and FDA in the USA. The use of the Calypso beacons is also conceivable for lung 
SBRT gating and couch tracking [75]. 
Our current clinical trial treats patients with lung tumours on a Trilogy Varian linac (Varian 
Medical Systems, Palo Alto, CA) using electromagnetic beacons inserted around the lesions 
[47]. Other groups have integrated the use of Calypso on a Siemens linac as a proof-of-concept 
but not to treat patients as yet [51]. The beacons are tracked in real-time with sub-2 mm position 
accuracy [76] and the beam is adapted using MLC tracking. This is the first and only institution 
treating patients with MLC tracking for lung SABR [47]. Patients (7/7) were successfully 
implanted, each with three beacons placed around the tumour, with positive dosimetric impact 
[77]. The underlying system latency of the MLC tracking system is approximately 220 ms [78] 
and is balanced with a kernel density-based method to predict the future target position [79]. 
 
3.5. Optical imaging 
Optical imaging can be used to monitor the patient’s abdomen or thorax for the patient’s 
positioning, therapeutic beam gating or real-time monitoring of lung SBRT. Although it has the 
advantage of being non-ionising and non-invasive, its main challenge is to provide an accurate 
correlation between external markers and internal motion despite potential tumour hysteresis. 
 
Optical imaging gating devices like the RPM system entail the use of an infra-red camera that 
illuminates a block covered with reflective markers positioned onto the patient’s abdomen. 
AlignRT (Vision RT, London, UK) and Catalyst (C-Rad AB, Uppsala, Sweden) map the patient 
surface contours. Other devices using reflective markers are the Cyberknife, Vero and ExacTrac, 
all described in an earlier section as they require regular fluoroscopic images to update the 
correlation model. The combination of optical imaging and kV imaging can improve this 
correlation with regular model updates during monitoring of the chest motion. All of these 
devices are used to monitor the patient’s abdomen or chest motion during DIBH, free-breathing 
gating or tumour tracking and detect unwanted patient movement like coughing and sneezing. It 
has been shown that DIBH combined with optical imaging decreases the dose to mediastinal 
structures as the inflated lung is caudally displaced away from the heart [80,81]. 
 
3.6. Breathing control devices 
Breathing control devices aim to manipulate the patient’s breathing pattern. They directly 
interact with the patient’s airflow with facial masks or restrict thoracic motion using devices to 
block the motion of the abdomen. Commercialised products that interact directly with the 
patient’s airflow through the mouth or nose are the Active Breathing Coordinator (ABC) device 
(Elekta AB, Stockholm, Sweden) and the SDX (Dyn’R, Toulouse, France). The ABC is a 
spirometer device dedicated to the practice of semi-voluntary breath-hold. It is connected to a 
balloon valve that blocks the patient air flow in several DIBH until the field is delivered, usually 
requiring two or three breath holds for the entire delivery. The SDX is also a spirometer device, 
however the patient is expected to perform breath-hold on their own with a pair of goggles 
providing instructions as a visual aid. The volume of air intakes is recorded from a flow sensor 
and converted into analogue signals. The signals are analysed by the SDX software that triggers 
the linac beam when the patient breathing curves reaches the breath-hold zone. 
 
A large clinical trial (STIC 2003) with 403 patients demonstrated significant dose reduction for 
patients that were treated with ABC or SDX compared with free-breathing or RPM gating 
technique [80]. Study showed that significant increase in lung volume were found with breathing 
control devices which resulted in noticeable higher dosimetric benefits compared with RPM 
gating techniques [82]. 
 
Another device, the Continuous Positive Air Pressure (CPAP device), is currently being tested 
for its potential clinical use in lung radiation therapy [83,84]. The original clinical use of the 
CPAP device was to avert blockage of upper airways for patients suffering from sleep apnoea. A 
continuous pressurised air flow is delivered to the patient’s airway by pumping air into the 
patient’s mouth or nose. The hypothesis is that continuous pressurised air results in a hyper-
inflated lung which stabilises the diaphragm and increases the distance between the tumour 
target and OAR (e.g. Heart). 
 
Other types of breathing control devices employ abdominal compression. Abdominal 
compression may be applied with several devices to mechanically restrict the motion of the 
abdomen during respiration. Since forced shallow breathing reduces the respiratory motion, dose 
escalation is permitted and beneficial for SBRT treatment. Compared with others forms of 
tracking or patient monitoring, the use of abdominal compression retains the advantages that its 
implementation is easy and accessible on linear accelerators and significantly reduces the cranio-
caudal motion. Abdominal compression is increasingly popular. A survey in 2013 showed that 
abdominal compression was used in 51% of clinical centres in the USA [85]. 
 
One form of abdominal compression is a paddle pressed against the patient’s abdomen, just 
below the ribs, using an arch system with screws to regulated the force of the paddle [86]. For 
this type of system, commercialised products are the Stradivarius abdominal compression paddle 
system (Qfix Systems, Avondale, PA), or the ONEBridge (Civco Medical Solutions, Kalona, IA) 
that comes in various sizes of respiratory plates. Another type of abdominal compression device, 
the pneumatic belt, applies pressure uniformly against the abdomen using an inflated belt 
controlled by a pump and a gauge. Commercialised products are the Stradivarius compression 
belt (Qfix), ONE Respiratory Belt (Civco Medical Solutions, Kalona, IA) and Omni V SBRT 
solution system (Bionix Radiation Therapy, Toledo, Ohio, US). It is worth noting that clinical 
centres have also designing their own custom-built external compression devices either for 
research purpose or to answer for their own specific needs [87,88]. 
 
Despite abdominal compression, patients may still experience upper body motion. Full thoracic 
motion restriction can be utilised to mitigate this problem. The BodyFIX system (Elekta, 
Medical Intelligence, Schwabmuenchen, Germany) is a dual-vacuum whole-body immobilisation 
device in which the patient is placed in a vacuum bag and the patient’s lower body, abdomen and 
thorax are wrapped in clear plastic. The air between the plastic, patient and the vacuum cushions 
is then evacuated [89,90]. Compared with the abdominal compression paddle, both techniques 
performed equivalently, although applying uniform compression to the body of the patient with 
the BodyFIX system was reported to be more comfortable [90]. Another type of body 
immobilisation is used with the Orfit SBRT body mask (Orfit Industries Nv, Wijnegem, 
Belgium). The body mask helps to immobilise the patient and is attached along specifically made 
slots. This technique is reported to be effective for treating patients with spinal metastases [91]. 
 
Objectives and implementation differ between centres depending on the strategies in place, 
clinical objectives of the centres and the type of patients treated. Forced shallow breathing with 
abdominal compression was shown to be most effective for patients with tumour motion 
exceeding 5 mm in free-breathing [92], or 13 mm for gating [93,94], with significant reduction in 
the cranio-caudal direction with the paddle compared with free-breathing [95] specially for lower 
lobe lesions [96]. However the reported residual excursion with the compression belt raises 
concerns about the tumour amplitude reproducibility [95]. 
 
3.7. Respiratory belt 
The use of a respiratory belt wrapped around the patient’s abdomen for monitoring or gating has 
also been tested. The most widely available systems are the Anzai belt (AZ-733V Anzai) 
manufactured by Siemens and the Bellows belt (Philips Medical System, Cleveland, OH). 
Respiratory belts are equipped with a strain gauge coupled with a sensor to record pressure 
variation induced by the chest stretching during breathing. The two-dimensional data is sent to 
the controller that triggers the beam according to the patient’s amplitude. Small groups of 
patients were treated with the respiratory belt [97,98] with evidence that gating provides a 
constant treatment quality control, depth dose and beam profile [99,100]. Respiratory gating with 
a belt or optical imaging remains a popular motion management technique with approximately 
31% of centres in USA using this with lung radiotherapy treatment [85]. 
 
3.8. Audio-visual biofeedback 
Coaching the patient to breathe regularly and/or showing them their respiratory trace for active 
patient control is known as Audio-visual feedback. The use of audio-visual biofeedback from 
monitoring devices to the patient allows the patient to actively participate in the treatment. The 
patient directly addresses irregular tumour motion by remaining within a threshold during DIBH 
or following a regular and predictable breathing pattern that is beneficial for tumour tracking 
devices. Breathing signals can be obtained from the RPM, belt, optical cameras or other devices 
providing an analogue output that can be redirected back to the patient. In a systematic review, 
most studies reported beneficial effects of the use of audio, visual or audio-visual biofeedback 
compared with free breathing [101]. 
 
3.9. Immobilisation devices 
Immobilisation of the patient is evidently paramount and can be obtained by locking the patient 
in a vacuum-lock foam bag, stereotactic frame with wingboard and alpha-cradle, and 
immobilising their feet and knees. These steps minimise motion or wobbling during CBCT 
couch shift after the 3D/3D match. 
 
4. Conclusion and outlook 
This chapter is a review of the current use of IGRT and motion management techniques available 
in radiation therapy. It explores the various devices, commercial or still at the research stage, that 
are currently available for patients treated with lung SBRT. The use of IGRT and motion 
management prior to treatment are established standardised techniques and their dissemination in 
clinical practice is ongoing [85]. However, the clinical benefits of motion management during 
radiation therapy are hard to interpret. Clinical trials generally involve small cohorts of patients, 
and the treatment strategies between radiotherapy centres cover a large range of fractionations, 
lung staging or tumour lobe location as well as different treatment techniques (VMAT, IMRT). 
Also, comparison of motion management against the absence of motion management is difficult 
because of the lack of randomised controlled trials. For that reason, stronger clinical data for a 
large cohort of patients is needed to fully claim the benefits of motion management for lung 
SBRT. 
 
The rise of MRI-guided linear accelerators may provide a paradigm shift in the way lung SBRT 
is currently performed. Because of its high tissue contrast, MRI-guided capabilities are far 
superior to kV-based imaging, with better target and OAR delineations [6]. In addition, it does 
not require ionising radiation to image the internal anatomy and is therefore safer for the patient. 
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Fig. 1. Summary of motion management techniques available prior to treatment. 
 
  
 Fig. 2. Summary of IGRT and non-IGRT motion management techniques available during 
treatment. 
 
  
  
Fig. 3. A) Calypso tracking station with the electromagnetic arm B) fluoroscopic images of 
implanted beacons within vicinity of the tumour C) lung calypso beacons with the nitinol legs. 
 
